Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 8/20 | 0.50 |
| ▸ | PDE4A | P27815 | 4/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3991737 | 0.77 | RIPK1 (0.45) | RIPK1KMT2AHPGDNPC1RAB9A | |
| SCHEMBL989750 | 0.76 | BCHE (0.60) | RIPK1NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL19378053 | 0.76 | TP53 (0.41) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19378054 | 0.76 | TP53 (0.41) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL28284325 | 0.76 | TP53 (0.63) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5385517 | 0.75 | NUDT1 (0.49) | PDE5ANUDT1METAP2METAP1HPGD | |
| SCHEMBL6248126 | 0.74 | PDE5A (0.44) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9239194 | 0.74 | NUDT1 (0.59) | PDE5ANUDT1AURKAKMT2AMETAP2 | |
| SCHEMBL31404329 | 0.74 | NUDT1 (0.59) | PDE5ANUDT1AURKAKMT2AMETAP2 | |
| SCHEMBL5399298 | 0.74 | NUDT1 (0.44) | PDE5ANUDT1KMT2AMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318443-A1 | KINASE INHIBITORS | BONJOUKLIAN ROSANNE | 2009-12-24 | — | — | US | disclosed |
| US-7582652-B2 | Suppression cytokines, tumor necrosis factor; melanoma | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090036445-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036445-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | PDE5A 1623/4885PDE4A 1440/4885PDE4B 1593/4885 |
| US-20090318443-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | PDE5A 1623/4885PDE4A 1440/4885PDE4B 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.